Some aspects of immunotherapy in colon cancer
Colon cancer is known to be resistant to immunotherapy; however, during the last few years, researchers managed to identify a subgroup of patients that response to anti-PD-1 therapy. This encouraged molecular biologists, immunologists, and clinical oncologists to reconsider the role of immunotherapy...
Main Authors: | M. Yu. Fedyanin, Kh. Kh.-M. El’snukaeva, A. A. Tryakin, S. A. Tyulyandin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
“ABV-press” Publishing house”, LLC
2018-05-01
|
Series: | Тазовая хирургия и онкология |
Subjects: | |
Online Access: | https://ok.abvpress.ru/jour/article/view/239 |
Similar Items
-
Use of nivolumab for colon cancer with Lynch syndrome
by: G. A. Khakimov, et al.
Published: (2020-11-01) -
Immunotherapy and its advances in the management of head-and-neck cancer
by: Sajad Ahmad Buch, et al.
Published: (2019-01-01) -
Prospects of application of inhibitors of PD-1/PD-L1 checkpoints in malignant tumors of the stomach and esophagogastric junction
by: D. D. Sakaeva, et al.
Published: (2020-12-01) -
The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches
by: Anna Koumarianou, et al.
Published: (2021-01-01) -
Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)